Investigating Sleep Concerns in Cervical Dystonia

Area of Science:

• Neurology
• Sleep Medicine
• Clinical Research

Background:

• Sleep disturbances are complex in dystonia due to small cohorts and co-occurring pain and psychiatric issues.
• Understanding sleep patterns in cervical dystonia (CD) remains challenging.
• Existing research often overlooks the intricate relationship between sleep, pain, and mood in CD.

Purpose of the Study:

• To investigate the prevalence and characteristics of sleep concerns in individuals with cervical dystonia (CD).
• To evaluate the impact of OnabotulinumtoxinA treatment on sleep disturbances in CD patients.
• To identify factors, including non-motor symptoms, that influence sleep improvement in CD.

Main Methods:

• Longitudinal data from the CD-PROBE study were analyzed for toxin-naïve or injection-naïve CD subjects.
• The Cervical Dystonia Impact Profile was used to assess sleep disturbances.
• Multilevel mixed-effects models analyzed the impact of OnabotulinumtoxinA on sleep, controlling for covariates.

Main Results:

• Over half of CD patients (56%) reported significant sleep issues, including problems with sleep initiation, restfulness, maintenance, and duration.
• Initial OnabotulinumtoxinA treatment demonstrated a statistically significant improvement in sleep quality (P < 0.001).
• Motor severity (β: 0.20), mood (β: 0.36), and pain (β: 0.58) were significant predictors of sleep improvement over three treatment cycles.

Conclusions:

• Sleep concerns are a common and significant issue for individuals with cervical dystonia (CD).
• OnabotulinumtoxinA treatment provides both initial and sustained improvement in sleep for CD patients.
• The substantial impact of mood and pain on sleep underscores the importance of addressing non-motor symptoms in CD management.